By Adriano Marchese Theratechnologies shares were down Wednesday morning after the company reported that lower fiscal second-quarter sales of its main drugs.
The decision to fund medications to treat H.I.V.-AIDS patients in sub-Saharan Africa and the Caribbean flew in the face of expert advice. But the U.S. did it anyway.